Report Tools

Rigel Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report

Published: December 2012 · Publisher: MarketLine
Rigel Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc.
Report Type Company Profiles
Language English
Format Electronic (PDF)
Pages42
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-0084
Price € 129,00
Options
  • Description
  • Table of Contents
  • Ask a Question
Rigel Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company.

Features:

- Detailed information on Rigel Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Rigel Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Rigel Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Rigel Pharmaceuticals, Inc.
- Intelligence on Rigel Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Rigel Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Rigel Pharmaceuticals (Rigel) is a clinical stage drug development company engaged in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune disorders, and muscle and metabolic diseases. The company operates in the US. It is headquartered in South San Francisco, California and employed 145 people as of December 2010. The company recorded revenues of $125 million during the financial year ended December 2010 (FY2010), as compared to revenues of $0.8 million in FY2009. The operating profit of the company was $35.3 million during FY2010, as compared to operating loss of $112 million in FY2009. The net profit was $37.9 million in FY2010, as compared to net loss of $111.5 million in FY2009.

Reasons to Purchase:

- Gain understanding of Rigel Pharmaceuticals, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Rigel Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Rigel Pharmaceuticals, Inc.’s business structure, strategy and prospects

Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Company Snapshot
Rigel Pharmaceuticals, Inc.: Company Overview
Rigel Pharmaceuticals, Inc.: Overview and Key Facts
Rigel Pharmaceuticals, Inc.: Overview
Rigel Pharmaceuticals, Inc.: Key Facts
Rigel Pharmaceuticals, Inc.: Key Employees
Rigel Pharmaceuticals, Inc.: Key Employee Biographies
Rigel Pharmaceuticals, Inc.: Major Products and Services
Rigel Pharmaceuticals, Inc.: Company History
Rigel Pharmaceuticals, Inc.: Management Statement
Rigel Pharmaceuticals, Inc.: Locations and Subsidiaries
Rigel Pharmaceuticals, Inc.: Key Competitors
Rigel Pharmaceuticals, Inc.: Company Analysis
Rigel Pharmaceuticals, Inc.: Business Description
Rigel Pharmaceuticals, Inc.: SWOT Analysis
Rigel Pharmaceuticals, Inc.: SWOT Overview
Rigel Pharmaceuticals, Inc.: Strengths
Rigel Pharmaceuticals, Inc.: Weaknesses
Rigel Pharmaceuticals, Inc.: Opportunities
Rigel Pharmaceuticals, Inc.: Threats
Rigel Pharmaceuticals, Inc.: Corporate Financial Deals Activity
Rigel Pharmaceuticals, Inc.: Financial Deals Overview
Rigel Pharmaceuticals, Inc.: Targets and Partners
Rigel Pharmaceuticals, Inc.: Top Deals 2009 - 2013YTD*
Rigel Pharmaceuticals, Inc.: Advisors
Rigel Pharmaceuticals, Inc.: Top Financial Advisors
Rigel Pharmaceuticals, Inc.: Capital Raising
Rigel Pharmaceuticals, Inc.: Partnership
Rigel Pharmaceuticals, Inc.: Recent Developments
Rigel Pharmaceuticals, Inc.: News and Events Summary
Rigel Pharmaceuticals, Inc.: Contracts
Rigel Pharmaceuticals, Inc.: Financial Performance
Rigel Pharmaceuticals, Inc.: Research & Development
Rigel Pharmaceuticals, Inc.: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions


List of Tables

Table 1: Rigel Pharmaceuticals, Inc.: Key Facts
Table 2: Rigel Pharmaceuticals, Inc.: Key Employees
Table 4: Rigel Pharmaceuticals, Inc.: Key Competitors
Table 5: Rigel Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 6: Rigel Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 7: Rigel Pharmaceuticals, Inc.: Targets and Partners
Table 8: Rigel Pharmaceuticals, Inc.: Top Deals 2009 - 2013YTD*
Table 9: Rigel Pharmaceuticals, Inc.: Financial Advisor Ranking by Value (US$m)
Table 10: Rigel Pharmaceuticals, Inc.: Capital Raising Volume and Value Trend (2009 - YTD*2013)
Table 11: Rigel Pharmaceuticals, Inc.: Capital Raising by Deal Type (2009 - YTD*2013)
Table 12: Rigel Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 13: Rigel Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 14: Rigel Pharmaceuticals, Inc.: News and Events Summary
Table 15: Rigel Pharmaceuticals, Inc.: Contracts
Table 16: Rigel Pharmaceuticals, Inc.: Financial Performance
Table 17: Rigel Pharmaceuticals, Inc.: Research & Development
Table 18: Rigel Pharmaceuticals, Inc.: Strategy and Operations

List of Figures

Figure 1: Rigel Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Rigel Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 3: Rigel Pharmaceuticals, Inc.: Capital Raising Volume and Value Trend (2009 - YTD*2013)
Figure 4: Rigel Pharmaceuticals, Inc.: Capital Raising by Deal Type (2009 - YTD*2013)
Figure 5: Rigel Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 6: Rigel Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.